RXRX Q1 2025 Earnings — Recursion Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RXRXRecursion Pharmaceuticals, Inc.

$2B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$15M+9.3% YoY

Gross Profit

-$7M-48.0% margin

Operating Income

-$191M-1297.9% margin

Net Income

-$202M-1373.3% margin

EPS (Diluted)

$-0.50

QoQ Revenue Growth

+226.9%

Cash Flow

Operating Cash Flow

-$132M

Free Cash Flow

-$134M

Stock-Based Comp.

$36M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$371M

Stockholders' Equity

$934M

Cash & Equivalents

$500M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$15M	$13M	+9.3%
Gross Profit	-$7M	$2M	-404.7%
Operating Income	-$191M	-$96M	-98.6%
Net Income	-$202M	-$91M	-121.6%

Revenue Segments

License and Service

$15M100%

Geographic Segments

UNITED STATES

$9M100%